Brief: Syncona Says Anv419 Continues To Demonstrate Potentially Differentiated Safety Profile To Approved Il-2 Therapies

Syncona

16/10/2023 07:24

Oct 16 (Reuters) - Syncona Ltd  SYNCS.L :
    * SYNCONA - OVERALL, ANV419 CONTINUES TO DEMONSTRATE A
POTENTIALLY
DIFFERENTIATED SAFETY PROFILE TO APPROVED IL-2 THERAPIES
    * SYNCONA - ANV419, AT A DOSE OF 243 ΜG/KG EVERY TWO WEEKS,
WAS
DETERMINED AS RECOMMENDED PHASE II DOSE
    * SYNCONA - ONE INJECTION OF ANV419 AT DOSE LEVEL DELIVERS
MORE
IL-2 EXPOSURE THAN FULL CYCLE OF AN APPROVED IL-2 THERAPY
    * SYNCONA - DURABLE RESPONSE WAS OBSERVED IN ONE PATIENT
WITH
ADVANCED IMMUNOTHERAPY-RESISTANT NON-SMALL CELL LUNG CANCER


 ((Reuters.Briefs@thomsonreuters.com;;))